InflaRx (IFRX) CEO reports 1,068,908 shares plus option grants

Rhea-AI Filing Summary

InflaRx N.V. Chief Executive Officer Niels Riedemann has filed an initial statement of beneficial ownership, detailing his current equity position in the company. He directly holds 1,068,908 Ordinary Shares and multiple stock option awards over additional Ordinary Shares at exercise prices ranging from $0.0152 to $2.44 per share, with expirations extending through 2050.

Most of these options were granted between 2012 and 2025 and are described as fully vested and exercisable as of the filing date. A January 6, 2026 option grant vests in four equal quarterly installments of 158,750 shares, subject to continued service, and a separate performance stock option grant tied to that date will vest in two 50% tranches based on a specified financing event before the fourth quarter of 2026 and the average Ordinary Share price in the fourth quarter of 2026 exceeding $1.50.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Riedemann Niels

(Last) (First) (Middle)

C/O INFLARX N.V.

WINZERLAER STREET 2

(Street)

JENA 07745

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
InflaRx N.V. [ IFRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	1,068,908	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	12/31/2050	Ordinary Shares	126,005	$0.0152	D
Stock Option (Right to Buy)	(2)	11/18/2031	Ordinary Shares	404,040	$1.86	D
Stock Option (Right to Buy)	(3)	12/13/2027	Ordinary Shares	689,253	$1.86	D
Stock Option (Right to Buy)	(4)	11/20/2028	Ordinary Shares	5,409	$1.86	D
Stock Option (Right to Buy)	(5)	01/04/2031	Ordinary Shares	350,000	$1.86	D
Stock Option (Right to Buy)	(6)	07/01/2031	Ordinary Shares	112,007	$1.86	D
Stock Option (Right to Buy)	(7)	01/11/2032	Ordinary Shares	548,000	$1.86	D
Stock Option (Right to Buy)	(8)	11/21/2032	Ordinary Shares	55,000	$2.44	D
Stock Option (Right to Buy)	(9)	01/24/2033	Ordinary Shares	548,000	$2.37	D
Stock Option (Right to Buy)	(10)	01/05/2034	Ordinary Shares	635,000	$1.79	D
Stock Option (Right to Buy)	(11)	01/03/2035	Ordinary Shares	635,000	$2.41	D
Stock Option (Right to Buy)	(12)	01/06/2036	Ordinary Shares	635,000	$1.17	D
Performance Stock Option (Right to Buy)	(13)	01/06/2036	Ordinary Shares	190,500	$1.17	D

Explanation of Responses:

1. This option was granted on November 15, 2012 and is fully vested and exercisable as of the date hereof.

2. This option was granted on November 18, 2016 and is fully vested and exercisable as of the date hereof.

3. This option was granted on December 13, 2017 and is fully vested and exercisable as of the date hereof.

4. This option was granted on November 20, 2018 and is fully vested and exercisable as of the date hereof.

5. This option was granted on January 4, 2021 and is fully vested and exercisable as of the date hereof.

6. This option was granted on July 2, 2021 and is fully vested and exercisable as of the date hereof.

7. This option was granted on January 12, 2022 and is fully vested and exercisable as of the date hereof.

8. This option was granted on November 21, 2022 and is fully vested and exercisable as of the date hereof.

9. This option was granted on January 24, 2023 and is fully vested and exercisable as of the date hereof.

10. This option was granted on January 5, 2024 and is fully vested and exercisable as of the date hereof.

11. This option was granted on January 3, 2025 and is fully vested and exercisable as of the date hereof.

12. This option was granted on January 6, 2026 and will vest and become exercisable in four equal installments of 158,750 shares on each quarterly anniversary of such grant date, subject to continued service through such dates.

13. This option shall vest depending upon achievement of the following performance criteria: (i) 50% shall vest if a certain financing event takes place before the fourth quarter of 2026 and (ii) 50% shall vest if the average Ordinary Share price for quarter four of 2026 exceeds $1.50.

Remarks:

Exhibit List - Exhibit 24.1 Power of Attorney

	/s/ Christian Schmid, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Form 3 filing by InflaRx (IFRX) CEO report?

The Form 3 reports CEO Niels Riedemann’s existing equity holdings in InflaRx, including 1,068,908 Ordinary Shares and multiple stock option awards. It is an initial ownership statement and does not itself show new share purchases or sales.

How many InflaRx (IFRX) Ordinary Shares does the CEO directly own?

CEO Niels Riedemann directly owns 1,068,908 Ordinary Shares of InflaRx. This figure reflects his reported direct share position in the Form 3 and is separate from his additional stock option and performance stock option awards over further Ordinary Shares.

What stock options are disclosed for the InflaRx (IFRX) CEO in this filing?

The filing lists several stock option awards over Ordinary Shares with exercise prices from $0.0152 to $2.44 and expiration dates between 2027 and 2050. Many were granted from 2012 through 2025 and are described as fully vested and exercisable as of the filing date.

Are the InflaRx (IFRX) CEO’s options already vested and exercisable?

Most listed options were granted between 2012 and 2025 and are fully vested and exercisable as of the filing date. A January 6, 2026 option grant vests in four equal quarterly installments, subject to continued service, rather than being fully vested immediately.

What performance conditions apply to the InflaRx (IFRX) CEO’s performance stock options?

The performance stock option grant dated January 6, 2026 vests 50% if a specified financing event occurs before the fourth quarter of 2026 and 50% if the average Ordinary Share price for the fourth quarter of 2026 exceeds $1.50, as described in the filing footnotes.

Does this InflaRx (IFRX) Form 3 show any insider buying or selling activity?

The data reflects holdings and option positions, with transaction codes described as unknown and transaction counts categorized as holdings. The transaction summary shows no buy or sell entries, indicating the filing focuses on reporting existing positions rather than new trades.